Jobs / United States / Glaxosmithkline LLC
Cardio-Renal Discovery Disease Area Lead
Glaxosmithkline LLC · 🇺🇸 3 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
We create a place where people can grow, be their best, be safe, and feel welcome, valued and included. We offer a competitive salary, an annual bonus based on company performance, healthcare and wellbeing programmes, pension plan membership, and shares and savings programme. We embrace modern work practises; our Performance with Choice programme offers a hybrid working model, empowering you to find the optimal balance between remote and in-office work. Discover more about our company wide benefits and life at GSK on our webpage Life at GSK | GSK Discovery Disease Area Lead, Cardiovascular-Renal Diseases At GSK, we are dedicated to improving the quality of human life by leveraging scientific advancements to develop better medicines with reduced attrition. Through our Discovery Disease Area Leads (DDALs), we enable target identification, selection, and validation at scale, driving innovation and excellence across our R&D landscape. As the Discovery Disease Area Lead, Cardiovascular-Renal, you will be at the forefront of our mission, driving the discovery and validation of therapeutic targets for a range of diseases, such as chronic kidney disease, glomerulonephritis and cardiovascular conditions that are associated with metabolic dysfunction. You will lead a cross-functional, highly matrixed team of scientists, clinical staff, and pharma experts to identify and validate high-quality targets using large-scale experimental and in silico approaches. Your efforts will ultimately contribute to translating human disease phenotype information into actionable therapeutic innovations. Location: This role will be based at one of GSK’s R&D hub sites, in Stevenage, UK, or Upper Providence, PA, USA. The Discovery Disease Area Lead, Cardiovascular-Renal will be expected to spend at least 2-3 days / week on site. For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029. Key Responsibilities: Portfolio Execution – • Portfolio Generation and Oversight: Generate and oversee the pre-Commit to Target (C2T) project portfolio in the Renal and Cardio-Renal therapy area. • Target Delivery: Systematically deliver pools of high-potential targets that fulfill all C2T quality criteria based on therapeutic area-defined target medicine profiles for bespoke target validation • Senior Management Interface: Influence Senior R&D management by identifying and communicating portfolio risks and opportunities. • Strategy Execution: Drive development and implementation of key components of the renal and cardio-renal research strategy in R&D Tech for the Research Units. • Team Representation: Ensure appropriate representation of lines/functions within the operational matrix team. Cardiovascular / renal / metabolic disease expertise - • Nephrology and/or Cardiovascular Expertise: Apply deep experience in renal and cardio-renal disease indications drug discovery, focusing on clinically relevant target identification through human-first discovery approaches. • Scientific Excellence: Drive best-in-class science across R&D Technologies and Research Units (RUs). • Strategic Partnership: Partner proactively with Research Units and R&D Technology Leadership to provide strategic scientific input into disease phenotype discovery and therapeutic target identification. • External Engagement : Maintain connection with renal biology experts, KOLs, and societies to ensure solid strategic guidance on emerging therapeutics, understanding which could impa